Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial

Sunil Suhas Solomon, Thomas C. Quinn, Suniti Solomon, Allison M. McFall, Aylur K. Srikrishnan, Vinita Verma, Muniratnam S. Kumar, Oliver Laeyendecker, David D. Celentano, Syed H. Iqbal, Santhanam Anand, Canjeevaram K. Vasudevan, Shanmugam Saravanan, David L. Thomas, Kuldeep Singh Sachdeva, Gregory M. Lucas, Shruti H. Mehta

Research output: Contribution to journalArticle

Abstract

Background & Aims: There have been calls to integrate HCV testing into existing services, including harm reduction and HIV prevention and treatment, but there are few empirical trials to date. We evaluated the impact of integrating HCV testing/education into integrated care centers (ICCs) delivering HIV services to people who inject drugs (PWID) across India, using a cluster-randomized trial. Methods: We compared ICCs with usual care in the PWID stratum (12 sites) of a 22-site cluster-randomized trial. In 6 sites, ICCs delivering HIV testing, harm reduction, other preventive services and linkage to HIV treatment were scaled from opioid agonist therapy centers and operated for 2 years. On-site rapid HCV antibody testing was integrated after 1 year. To assess impact, we conducted baseline and evaluation surveys using respondent-driven sampling (RDS) across the 12 sites (n = 11,993 recruited at baseline; n = 11,721 recruited at evaluation). The primary outcome was population-level self-reported HCV testing history. Results: At evaluation, HCV antibody prevalence ranged from 7.2–76.6%. Across 6 ICCs, 5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed. At evaluation, PWID in ICC clusters were 4-fold more likely to report being tested for HCV than in usual care clusters, adjusting for baseline testing (adjusted prevalence ratio [aPR] 3.69; 95% CI 1.34–10.2). PWID in ICC clusters were also 7-fold more likely to be aware of their HCV status (aPR 7.11; 95% CI 1.14–44.3) and significantly more likely to initiate treatment (aPR 9.86; 95% CI 1.52–63.8). Conclusions: We provide among the first empirical data supporting the integration of HCV testing into HIV/harm reduction services. To achieve elimination targets, programs will need to scale-up such venues to deliver comprehensive HCV services. ClinicalTrials.gov identifier: NCT01686750. Lay summary: Delivering hepatitis C virus (HCV) testing to people who inject drugs (PWID) in places where they also have access to HIV prevention and treatment services is an effective way to improve uptake of HCV testing among communities of PWID. To achieve the World Health Organization's ambitious elimination targets, integrated programs will need to be scaled up to deliver comprehensive HCV services.

Original languageEnglish (US)
JournalJournal of Hepatology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Hepatitis C
Hepacivirus
HIV
Pharmaceutical Preparations
Harm Reduction
Hepatitis C Antibodies
Opioid Analgesics
India
History
Education

Keywords

  • Cluster-randomised trial
  • HCV
  • Hepatitis C virus
  • HIV
  • India
  • Integrated care
  • People who inject drugs
  • PWID

ASJC Scopus subject areas

  • Hepatology

Cite this

Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs : A cluster-randomized trial. / Solomon, Sunil Suhas; Quinn, Thomas C.; Solomon, Suniti; McFall, Allison M.; Srikrishnan, Aylur K.; Verma, Vinita; Kumar, Muniratnam S.; Laeyendecker, Oliver; Celentano, David D.; Iqbal, Syed H.; Anand, Santhanam; Vasudevan, Canjeevaram K.; Saravanan, Shanmugam; Thomas, David L.; Sachdeva, Kuldeep Singh; Lucas, Gregory M.; Mehta, Shruti H.

In: Journal of Hepatology, 01.01.2019.

Research output: Contribution to journalArticle

Solomon, SS, Quinn, TC, Solomon, S, McFall, AM, Srikrishnan, AK, Verma, V, Kumar, MS, Laeyendecker, O, Celentano, DD, Iqbal, SH, Anand, S, Vasudevan, CK, Saravanan, S, Thomas, DL, Sachdeva, KS, Lucas, GM & Mehta, SH 2019, 'Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial', Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.09.022
Solomon, Sunil Suhas ; Quinn, Thomas C. ; Solomon, Suniti ; McFall, Allison M. ; Srikrishnan, Aylur K. ; Verma, Vinita ; Kumar, Muniratnam S. ; Laeyendecker, Oliver ; Celentano, David D. ; Iqbal, Syed H. ; Anand, Santhanam ; Vasudevan, Canjeevaram K. ; Saravanan, Shanmugam ; Thomas, David L. ; Sachdeva, Kuldeep Singh ; Lucas, Gregory M. ; Mehta, Shruti H. / Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs : A cluster-randomized trial. In: Journal of Hepatology. 2019.
@article{13c61c7d0b0c48008566d12407d47840,
title = "Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial",
abstract = "Background & Aims: There have been calls to integrate HCV testing into existing services, including harm reduction and HIV prevention and treatment, but there are few empirical trials to date. We evaluated the impact of integrating HCV testing/education into integrated care centers (ICCs) delivering HIV services to people who inject drugs (PWID) across India, using a cluster-randomized trial. Methods: We compared ICCs with usual care in the PWID stratum (12 sites) of a 22-site cluster-randomized trial. In 6 sites, ICCs delivering HIV testing, harm reduction, other preventive services and linkage to HIV treatment were scaled from opioid agonist therapy centers and operated for 2 years. On-site rapid HCV antibody testing was integrated after 1 year. To assess impact, we conducted baseline and evaluation surveys using respondent-driven sampling (RDS) across the 12 sites (n = 11,993 recruited at baseline; n = 11,721 recruited at evaluation). The primary outcome was population-level self-reported HCV testing history. Results: At evaluation, HCV antibody prevalence ranged from 7.2–76.6{\%}. Across 6 ICCs, 5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed. At evaluation, PWID in ICC clusters were 4-fold more likely to report being tested for HCV than in usual care clusters, adjusting for baseline testing (adjusted prevalence ratio [aPR] 3.69; 95{\%} CI 1.34–10.2). PWID in ICC clusters were also 7-fold more likely to be aware of their HCV status (aPR 7.11; 95{\%} CI 1.14–44.3) and significantly more likely to initiate treatment (aPR 9.86; 95{\%} CI 1.52–63.8). Conclusions: We provide among the first empirical data supporting the integration of HCV testing into HIV/harm reduction services. To achieve elimination targets, programs will need to scale-up such venues to deliver comprehensive HCV services. ClinicalTrials.gov identifier: NCT01686750. Lay summary: Delivering hepatitis C virus (HCV) testing to people who inject drugs (PWID) in places where they also have access to HIV prevention and treatment services is an effective way to improve uptake of HCV testing among communities of PWID. To achieve the World Health Organization's ambitious elimination targets, integrated programs will need to be scaled up to deliver comprehensive HCV services.",
keywords = "Cluster-randomised trial, HCV, Hepatitis C virus, HIV, India, Integrated care, People who inject drugs, PWID",
author = "Solomon, {Sunil Suhas} and Quinn, {Thomas C.} and Suniti Solomon and McFall, {Allison M.} and Srikrishnan, {Aylur K.} and Vinita Verma and Kumar, {Muniratnam S.} and Oliver Laeyendecker and Celentano, {David D.} and Iqbal, {Syed H.} and Santhanam Anand and Vasudevan, {Canjeevaram K.} and Shanmugam Saravanan and Thomas, {David L.} and Sachdeva, {Kuldeep Singh} and Lucas, {Gregory M.} and Mehta, {Shruti H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jhep.2019.09.022",
language = "English (US)",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",

}

TY - JOUR

T1 - Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs

T2 - A cluster-randomized trial

AU - Solomon, Sunil Suhas

AU - Quinn, Thomas C.

AU - Solomon, Suniti

AU - McFall, Allison M.

AU - Srikrishnan, Aylur K.

AU - Verma, Vinita

AU - Kumar, Muniratnam S.

AU - Laeyendecker, Oliver

AU - Celentano, David D.

AU - Iqbal, Syed H.

AU - Anand, Santhanam

AU - Vasudevan, Canjeevaram K.

AU - Saravanan, Shanmugam

AU - Thomas, David L.

AU - Sachdeva, Kuldeep Singh

AU - Lucas, Gregory M.

AU - Mehta, Shruti H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background & Aims: There have been calls to integrate HCV testing into existing services, including harm reduction and HIV prevention and treatment, but there are few empirical trials to date. We evaluated the impact of integrating HCV testing/education into integrated care centers (ICCs) delivering HIV services to people who inject drugs (PWID) across India, using a cluster-randomized trial. Methods: We compared ICCs with usual care in the PWID stratum (12 sites) of a 22-site cluster-randomized trial. In 6 sites, ICCs delivering HIV testing, harm reduction, other preventive services and linkage to HIV treatment were scaled from opioid agonist therapy centers and operated for 2 years. On-site rapid HCV antibody testing was integrated after 1 year. To assess impact, we conducted baseline and evaluation surveys using respondent-driven sampling (RDS) across the 12 sites (n = 11,993 recruited at baseline; n = 11,721 recruited at evaluation). The primary outcome was population-level self-reported HCV testing history. Results: At evaluation, HCV antibody prevalence ranged from 7.2–76.6%. Across 6 ICCs, 5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed. At evaluation, PWID in ICC clusters were 4-fold more likely to report being tested for HCV than in usual care clusters, adjusting for baseline testing (adjusted prevalence ratio [aPR] 3.69; 95% CI 1.34–10.2). PWID in ICC clusters were also 7-fold more likely to be aware of their HCV status (aPR 7.11; 95% CI 1.14–44.3) and significantly more likely to initiate treatment (aPR 9.86; 95% CI 1.52–63.8). Conclusions: We provide among the first empirical data supporting the integration of HCV testing into HIV/harm reduction services. To achieve elimination targets, programs will need to scale-up such venues to deliver comprehensive HCV services. ClinicalTrials.gov identifier: NCT01686750. Lay summary: Delivering hepatitis C virus (HCV) testing to people who inject drugs (PWID) in places where they also have access to HIV prevention and treatment services is an effective way to improve uptake of HCV testing among communities of PWID. To achieve the World Health Organization's ambitious elimination targets, integrated programs will need to be scaled up to deliver comprehensive HCV services.

AB - Background & Aims: There have been calls to integrate HCV testing into existing services, including harm reduction and HIV prevention and treatment, but there are few empirical trials to date. We evaluated the impact of integrating HCV testing/education into integrated care centers (ICCs) delivering HIV services to people who inject drugs (PWID) across India, using a cluster-randomized trial. Methods: We compared ICCs with usual care in the PWID stratum (12 sites) of a 22-site cluster-randomized trial. In 6 sites, ICCs delivering HIV testing, harm reduction, other preventive services and linkage to HIV treatment were scaled from opioid agonist therapy centers and operated for 2 years. On-site rapid HCV antibody testing was integrated after 1 year. To assess impact, we conducted baseline and evaluation surveys using respondent-driven sampling (RDS) across the 12 sites (n = 11,993 recruited at baseline; n = 11,721 recruited at evaluation). The primary outcome was population-level self-reported HCV testing history. Results: At evaluation, HCV antibody prevalence ranged from 7.2–76.6%. Across 6 ICCs, 5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed. At evaluation, PWID in ICC clusters were 4-fold more likely to report being tested for HCV than in usual care clusters, adjusting for baseline testing (adjusted prevalence ratio [aPR] 3.69; 95% CI 1.34–10.2). PWID in ICC clusters were also 7-fold more likely to be aware of their HCV status (aPR 7.11; 95% CI 1.14–44.3) and significantly more likely to initiate treatment (aPR 9.86; 95% CI 1.52–63.8). Conclusions: We provide among the first empirical data supporting the integration of HCV testing into HIV/harm reduction services. To achieve elimination targets, programs will need to scale-up such venues to deliver comprehensive HCV services. ClinicalTrials.gov identifier: NCT01686750. Lay summary: Delivering hepatitis C virus (HCV) testing to people who inject drugs (PWID) in places where they also have access to HIV prevention and treatment services is an effective way to improve uptake of HCV testing among communities of PWID. To achieve the World Health Organization's ambitious elimination targets, integrated programs will need to be scaled up to deliver comprehensive HCV services.

KW - Cluster-randomised trial

KW - HCV

KW - Hepatitis C virus

KW - HIV

KW - India

KW - Integrated care

KW - People who inject drugs

KW - PWID

UR - http://www.scopus.com/inward/record.url?scp=85075399660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075399660&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2019.09.022

DO - 10.1016/j.jhep.2019.09.022

M3 - Article

C2 - 31604081

AN - SCOPUS:85075399660

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -